Proteins and Peptides

7 July 2016

Sanofi Genzyme Begins Pivotal Phase 2/3 Trial of Olipudase Alfa for Adult Patients with Acid Sphingomyelinase Deficiency

6 July 2016

Cinfa Biotech announces positive top-line clinical data of pegfilgrastim biosimilar candidate B12019

4 July 2016

European Commission Approves Extended Indication For Amgen’s Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients

30 June 2016

Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants

29 June 2016

Aurinia Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN)

28 June 2016

Glide Technologies Announces Successful Clinical Proof-of-Concept Study with its Novel Octreotide Solid Dose Formulation Delivered via SDI

27 June 2016

Tarix Orphan Announces Positive Results with TXA127 in Animal Model of Dystrophic Epidermolysis Bullosa (DEB)

27 June 2016

Stealth BioTherapeutics Initiates Two Phase 2 Trials Evaluating Elamipretide for the Treatment of Heart Failure

23 June 2016

Apellis Announces Positive Results from Phase 1 Clinical Trials of APL-2, a C3 Complement Inhibitor

23 June 2016

Angiochem Announces Successful End-of-Phase 2 Meeting With FDA for ANG1005

22 June 2016

AntriaBio Announces Preclinical Proof of Concept for Once-Weekly Basal Insulin AB101 in Diabetic Miniature Swine

22 June 2016

Cytonics Announces That Its Recombinant A2M Variants Attenuate Cartilage Degeneration in OA Models

17 June 2016

Auris Medical Initiates ASSENT Phase 3 Trial of AM-111 for Treatment of Sudden Deafness

17 June 2016

Stealth BioTherapeutics Reports Positive Elamipretide Data in First-Of-Its-Kind Primary Mitochondrial Myopathy Trial

15 June 2016

Noveome Initiates Phase 2 Clinical Trial of ST266 to Treat Patients with Periodontitis

14 June 2016

PharmaMar announces the start of a pivotal study with plitidepsin in angioimmunoblastic T-cell lymphoma

14 June 2016

Revance Reports Results for RT001 Topical Phase 3 Trial for Lateral Canthal Lines

14 June 2016

Victoza® Significantly Reduced the Risk of Major Adverse Cardiovascular Events in the LEADER Trial

13 June 2016

BioSpecifics Technologies Corp. Announces Positive Top-Line Results from Phase 2 Trial of CCH for Treatment of Human Lipoma

13 June 2016

Eiger Announces Positive Clinical Results of Single Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Post-Bariatric Hypoglycemia

13 June 2016

Merck’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus

13 June 2016

Faster-acting insulin aspart showed a statistically significant reduction in HbA1c in type 1 diabetes and a comparable HbA1c reduction in type 2 diabetes versus NovoRapid® (insulin aspart)

13 June 2016

Intarcia Presents FREEDOM-2 Trial Results in Type 2 Diabetes Demonstrating Clinically Meaningful Superiority and Sustained Glucose Control and Weight Reduction for ITCA 650 vs. Januvia®: Oral Presentation at ADA 76th Scientific Sessions

13 June 2016

AstraZeneca Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes

13 June 2016

Janssen’s EPREX® (epoetin alfa) Demonstrates Effectiveness as a Treatment for Anaemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

13 June 2016

New Data Show Lilly’s Once-Weekly Trulicity® (dulaglutide) in Combination with Insulin Glargine Improves Glycemic Control in People with Type 2 Diabetes

13 June 2016

Tresiba(R) (insulin degludec injection U-100) demonstrated significantly lower rates of overall, nocturnal and severe hypoglycaemia vs insulin glargine U-100

13 June 2016

Semaglutide demonstrated superior improvements in glycaemic control vs sitagliptin (SUSTAIN 2) and exenatide ER (SUSTAIN 3) in two clinical trials in adults with type 2 diabetes

13 June 2016

Sanofi Announces Positive Phase 3 Results for Investigational Titratable Fixed-Ratio Combination of Insulin Glargine and Lixisenatide

10 June 2016

Sophiris Bio Reports Successful Results from Completed Phase 2a Study of Topsalysin in Localized Prostate Cancer

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

c-Met-Targeted Antibody Therapy Pipeline Review

GPC3-Targeted Immunotherapy Pipeline Review

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

PD-1 Agonists Pipeline Review

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review